CN Bio and the University of Melbourne Collaborate to Advance Therapies for Respiratory Complications in Recovered COVID-19 Patients
CN Bio’s Lung-on-a-Chip technology will enable research into therapies to prevent interstitial lung disease and long-term lung impairment, following SARS-CoV-2 infection CN Bio, a leading cell culture company, that has ...